BORDERLINE RESECTABLE PANCREATIC ADENOCARCINOMA
Clinical trials for BORDERLINE RESECTABLE PANCREATIC ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new BORDERLINE RESECTABLE PANCREATIC ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for BORDERLINE RESECTABLE PANCREATIC ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail aims to tackle tough pancreatic cancer
Disease control Recruiting nowThis study tests whether adding two new drugs (zimberelimab and quemliclustat) to standard chemotherapy can help shrink pancreatic tumors that are either borderline removable or have spread locally. About 56 adults with untreated pancreatic cancer will receive the combination. Th…
Matched conditions: BORDERLINE RESECTABLE PANCREATIC ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New hope for tough pancreatic cancers: drug combo aims to shrink tumors before surgery
Disease control Recruiting nowThis early-phase trial tests a new drug called PTM-101 given alongside standard chemotherapy for people with pancreatic cancer that is either borderline resectable or locally advanced (meaning it has not spread far but is hard to remove surgically). The goal is to see if adding P…
Matched conditions: BORDERLINE RESECTABLE PANCREATIC ADENOCARCINOMA
Phase: PHASE1 • Sponsor: PanTher Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New chemo sequence aims to make pancreatic tumors operable
Disease control Recruiting nowThis phase 2 trial is testing whether giving two different chemotherapy regimens one after the other can shrink pancreatic tumors that are borderline or locally advanced, making them easier to remove surgically. The study enrolls 64 adults with pancreatic adenocarcinoma. Particip…
Matched conditions: BORDERLINE RESECTABLE PANCREATIC ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Wake Forest University Health Sciences • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Triple punch against pancreatic cancer: chemo, immunotherapy, and radiation before surgery
Disease control Recruiting nowThis study is testing a new approach for people with pancreatic cancer that can be surgically removed. Before surgery, patients receive a combination of chemotherapy (mFOLFIRINOX), an immunotherapy drug (pembrolizumab), and targeted radiation (SABR). After surgery, they continue …
Matched conditions: BORDERLINE RESECTABLE PANCREATIC ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Amsterdam UMC, location VUmc • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New hope for pancreatic cancer: targeted combo trial opens
Disease control Recruiting nowThis study tests a new combination of drugs (HRS-4642, nimotuzumab, and chemotherapy) in 40 people with a specific type of pancreatic cancer that has a KRAS G12D mutation and is borderline removable. The goal is to see if the treatment can shrink the tumor enough for surgery and …
Matched conditions: BORDERLINE RESECTABLE PANCREATIC ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New chemo combo shows promise for tough pancreatic tumors
Disease control Recruiting nowThis study tests a new way of giving chemotherapy to people with pancreatic cancer that is on the edge of being removable. The goal is to shrink the tumor enough for successful surgery. About 35 adults will receive two different chemo drug combinations in alternating cycles. The …
Matched conditions: BORDERLINE RESECTABLE PANCREATIC ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Dartmouth-Hitchcock Medical Center • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC